2019. A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S18. DOI:https://doi.org/10.25251/skin.3.supp.18.